Effect of topical tretinoin under occlusion on atypical naevi

Melanoma Research

Volumn 8, Issue 6, 1998, Pages 539-548

  Stam Posthuma, J J ^a   Vink, J ^a   Le Cessie, S ^a   Bruijn, J A ^a   Bergman, W ^a   Pavel, S ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Atypical naevi; Occlusion; Topical tretinoin

Indexed keywords

ACTIDERM; HYDROCORTISONE; PLACEBO; RETINOIC ACID;

ADULT; ARTICLE; CANCER PREVENTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HISTOLOGY; HUMAN; MALE; MELANOMA; NEVUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN CANCER; TREATMENT OUTCOME;

EID: 0032416521     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-199812000-00009     Document Type: Article

References (44)

1. Lee JA. The rising incidence of cutaneous malignant melanoma. Am J Dermatopathol 1985; 7(suppl): 35-39.
2. Glass AG, Hoover RN. The emerging epidemic of melanoma and squamous cell skin cancer. JAMA 1989; 262: 2097-2100.
3. MacLennan R, Green AC, McLeod GR, et al. Increasing incidence of cutaneous melanoma in Queensland, Australia. J Natl Cancer Inst 1992; 84: 1427-1432.
4. Burton RC, Coates MS, Hersey P, et al. An analysis of a melanoma epidemic. Int J Cancer 1993; 55: 765-770.
5. Friedman RJ, Heilman ER, Rigel DS, et al. The dysplastic nevus: clinical and pathologic features. Dermatol Clin 1985; 3: 239-249.
6. Greene MH. The dysplastic nevus syndrome: precursors of hereditary and nonfamilial cutaneous melanoma. In: Important Advances in Oncology. 1986: 173-191.
7. Marghoob AA, Kopf AW, Rigel DS, et al. Risk of cutaneous malignant melanoma in patients with classic atypical mole syndrome. Arch Dermatol 1994; 130: 993-998.
8. Weiss J, Garbe C, Buttner P, et al. Dysplastic nevidysplastic nevus syndromes: clinical features and genetic aspects. Recent Results Cancer Res 1993; 128: 101-118.
9. Elder DE, Greene MH, Bondi EE, et al. Acquired melanocytic nevi and melanoma: the dysplastic nevus syndrome. In Ackerman AB (ed.) Pathology of Malignant Melanoma. New York: Masson, 1981: 185-215.
10. Clark WH Jr, Elder DE, Guerry D IV, et al. A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum Pathol 1984; 15: 1147-1165.
11. Cook MG, Robertson I. Melanocytic dysplasia and melanoma. Histopathology 1985; 9: 647-658.
12. Kelly JW, Crutcher WA, Sagebiel RW. Clinical diagnosis of dysplastic melanocytic nevi. J Am Acad Dermatol 1986; 14: 1044-1052.
13. Elder DE, Kraemer KH, Greene MH, et al. The dysplastic nevus syndrome: our definition. Am J Acad Dermatopathol 1982; 4: 445-460.
14. Precursors to malignant melanoma. National Institutes of Health Consensus Development conference statement, Oct. 24-26, 1983. J Am Acad Dermatol 1984; 10: 683-688.
15. Greene MH, Clark WH Jr, Tucker MA, et al. High risk of malignant melanoma in melanoma prone families with dysplastic nevi. Ann Intern Med 1985; 102: 458-465.
16. Tiersten AD, Grin CM, Kopf AW, et al. Prospective follow-up for malignant melanoma in patients with atypical mole (dysplastic nevus) syndrome. J Dermatol Surg Oncol 1991; 17: 44-48.
17. Schneider JS, Moore DH, Sagebiel RW. Risk factors for melanoma incidence in prospective follow up: the importance of atypical (dysplastic) nevi. Arch Dermatol 1994; 130: 1002-1007.
18. Kopf AW. Prevention of malignant melanoma. Dermatol Clin 1985; 3: 351-352, 354, 358-360.
19. Lober CW. Dysplastic (atypical) nevi: significance and management. South Med J 1992; 85: 870-877.
20. Lotan R. Effects of vitamin A and its analogues (retinoids) on normal and neoplastic cells. Biochim Biophys Acta 1980; 605: 33-91.
21. Meyskens FL Jr. Modulation of abnormal growth by retinoids: a clinical perspective of the biological phenomenon. Life Sci 1981; 28: 2323-2327.
22. Lotan R, Giotta G, Nork E, et al. Characterization of the inhibitory effects of retinoids on the in vitro growth of two malignant murine melanomas. J Natl Cancer Inst 1978; 60: 1035-1041.
23. Lotan R. Different susceptibilities of human melanoma and breast carcinoma cell lines to retinoic acid induced growth inhibition. Cancer Res 1979; 39: 1014-1019.
24. Bergman MD, Peters E, Sander D, et al. Dexamethasone, prostaglandin A. and retinoic acid modulation of murine and human melanoma cells grown in soft agar. J Natl Cancer Inst 1983; 71: 927-932.
25. Meyskens FL Jr, Salmon SE. Inhibition of human melanoma colony formation by retinoids. Cancer Res 1979; 39: 4055-4057.
26. Meyskens FL Jr, Fuller BB. Characterization of the effects of different retinoids on the growth and differentiation of a human melanoma cell line and selected subclones. Cancer Res 1980; 40: 2194-2196.
27. Lippman SM, Meykens FL. Treatment of advanced squamous cell carcinoma of the skin with isotretinoin. Ann Intern Med 1987; 107: 499-501.
28. Bollag W. Vitamin A and vitamin A acid in the prophylaxis and therapy of epithelial tumours. Int J Vit Res 1970; 40: 299-314.
29. Cristofolini M, Zumiani G, Scappini P, Piscioli F. Aromatic retinoid in the chemoprevention of the progression of nevoid basal cell carcinoma syndrome. J Dermatol Surg Oncol 1984; 10: 778-781.
30. Felix EL, Loyd B, Cohen M. Inhibition of the growth and development of a transplantable murine melanoma by vitamin A. Science 1975; 189: 886-889.
31. Levine N, Meyskens FL Jr. Topical vitamin A acid therapy for cutaneous metastatic melanoma. Lancet 1980; ii: 224-226.
32. Meyskens FL Jr. Prevention and treatment of cancer with vitamin A and the retinoids. In: Prasad K, ed. Vitamins, Nutrition and Cancer. New York: S Karger, 1984: 226-273.
33. Edwards L, Meyskens F, Levine N. Effect of oral isotretinoin on dysplastic nevi. J Am Acad Dermatol 1989; 20: 257-260.
34. Edwards L, Jaffe P. The effect of topical tretinoin on dysplastic nevi. Arch Dermatol 1990; 126: 494-499.
35. Halpern AC, Schuchter LM, Elder DE, et al. Effects of topical tretinoin on dysplastic nevi. J Clin Oncol 1994; 12: 1028-1035.
36. Meyskens FL Jr, Edwards L, Levine NS. Role of topical tretinoin in melanoma and dysplastic nevi. J Am Acad Dermatol 1986; 15: 822-825.
37. Mooi WJ, Krausz T, Azzopardi JG. Biopsy Pathology of Melanocytic Disorders. London: Chapman and Hall, 1992: 192-204.
38. McCullagh P, Nelder JA. Generalized Linear Models. London: Chapman and Hall, 1989: 270-273.
39. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986; 42: 1019-1031.
40. Kraemer KH, DeGiovanna JJ, Moshell A, et al. Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. N Engl J Med 1988; 318: 1663-1637.
41. Peck GL, DeGiovanna JJ, Sarnoff DS, et al. Treatment and prevention of basal cell carcinoma with oral isotretinoin. J Am Acad Dermatol 1988; 19: 176-185.
42. Black WC, Hunt WC. Histologic correlations with the clinical diagnosis of dysplastic nevus. Am J Surg Pathol 1990; 14(1): 44-52.
43. Tronnier M, Smolle J, Wolff HH. Ultraviolet irradiation induces acute changes in melanocytic nevi. J Invest Dermatol 1995; 104: 475-478.
44. Stanganelli I, Bauer P, Bucchi L, et al. Critical effects of intense sun exposure on the expression of epiluminescence microscopy features of acquired melanocytic nevi. Arch Dermatol 1997; 133(8): 979-982.